Cancer Treatment News and Research

RSS

US Oncology Specialty passes VAWD accreditation program

US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.

15 May 2010

Still River Systems announces clinical beam extraction from world's smallest high-energy proton therapy accelerator

Still River Systems, Inc. announces successful clinical beam extraction from the first production unit of the world's smallest high-energy proton therapy accelerator. Powerful proton beams are used for the precise treatment of cancer by delivering a highly focused beam of radiation to the tumor while reducing the damage to surrounding healthy tissue and vital organs.

15 May 2010

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

Johns Hopkins Children's Center neonatologist Christoph Lehmann, M.D., has joined the nation's leading watchdog organization on health-care quality, the National Quality Forum (NQF), as a member of its newly formed Health Information Technology (HIT) advisory committee.

14 May 2010

Increase in use of imaging scans underscores need for evidence-based protocols in cancer care

New research showing a more than 30 percent annual increase in the use of high-tech imaging scans in older cancer patients underscores the need for evidence-based protocols in cancer care, said MedSolutions, a leading provider of medical management services.

14 May 2010

CIGNA adds CTCA to national network

Recognizing the importance of access, quality and choice for its many customers who have been touched by cancer, CIGNA has entered into a new agreement that opens the doors to comprehensive, integrative care at Cancer Treatment Centers of America (CTCA).

14 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 third quarter, ended March 31, 2010.

12 May 2010

Genetic tests represent future of cancer care for women

Important progress is being made in women's health through the use of genetic tests, particularly those that help women detect and treat cancer.

12 May 2010

New computer-based tool developed to benefit cancer patients

Cancer patients and doctors are finally getting on the same page about cancer survivorship, thanks to a free new tool that can benefit anyone who has been diagnosed with cancer.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Cancer costs double in 20 years but are still in line with overall health spending, study finds

USA Today: "The cost of treating cancer has doubled over the past 20 years, but those costs are in line with overall trends in health spending. And while more people are getting cancer as the U.S. population ages, treatment has shifted away from hospitals to outpatient settings, finds a study in Monday's edition of the journal Cancer.

11 May 2010

Personalized treatments for thyroid disorders to be presented at ATA meeting

Internationally recognized thyroid disease experts will meet to discuss "Thyroid Disorders in the Era of Personalized Medicine" May 13 - 16 in Minneapolis, Minnesota at the American Thyroid Association's (ATA) (www.thyroid.org) Spring Meeting to be held at the Minneapolis Hyatt Regency Hotel.

11 May 2010

Costs and quality of cancer care in the U.S.

A new analysis finds that the costs of treating cancer have nearly doubled over the past two decades and that the shares of these costs that are paid for by private health insurance and Medicaid have increased.

10 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Decisive impact of informatics on nanomedicine

According to what researchers from Facultad de Informática and other institutions have advanced in an article just published in the prestigious medical journal Pediatric Research (Vol.6, No. 5, 2010), nanoparticles are poised to play a key role in medical research in the coming decades, when nanomedicine will become part of medical practice.

5 May 2010